September 2018 By Dr Matthew Callister, Consultant Respiratory Physician CT screening in Europe took a leap forward this week with the publication of the mortality results from the NELSON screening study. NELSON was a population-based controlled trial that ran in the … Read More
August 2018 By Tom Newsom-Davis, Consultant Oncologist On 26th July 2018 one of the European Medicines Agency (EMA) committees recommended that the immunotherapy drug, Durvalumab, be licensed for use in patients with locally advanced (stage III) lung cancer. Although this does not mean … Read More
The BTOG Position Statement 2018 is now available. This document provides the brief background of BTOG and achievements to date and confirms BTOG’s Core Principles and Key Activities. Please view here. British Thoracic Oncology Group Position Statement Final July 2018
Download the BTOG Annual Report (April 2016 to March 2017).
Article from the European Journal of Cancer: Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial Please see article.
ASCO 2017 National Update – Roy Castle Lung Cancer Foundation in partnership with BTOG Friday 9th June 2017 – Wellcome Collection, London The main focus for this Roy Castle Lung Castle Foundation meeting, planned in partnership with the British Thoracic … Read More
Dr Sanjay Popat is Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Honorary Clinical Senior Lecturer in the Molecular Genetics and Genomics Group at the National Heart and Lung Institute, Imperial College London. Dr Popat has published in … Read More